SG
ACET icon

StoneX Group’s Adicet Bio ACET Stock Holding History

StoneX Group’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-778
Closed -$9.4K – 870
2025
Q1 		$9.4K Buy
+778
New +$11.1K ﹤0.01% 822

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

StoneX Group's ACET Position: Q2 2025 in Review

StoneX Group sold out of Adicet Bio (ACET) in Q2 2025, closing a stake of 778 shares — an estimated $9.4K sold.

StoneX Group first reported a position in ACET in Q1 2025 and held it in 1 quarter. The position peaked at $9.4K in Q1 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q2 2025.

  • StoneX Group reported no remaining Adicet Bio position as of Q2 2025 after selling out during the quarter.
  • StoneX Group sold 778 Adicet Bio shares in Q2 2025, an estimated $9.4K.
  • StoneX Group first reported a position in Adicet Bio in Q1 2025 and held it in 1 quarter.
  • StoneX Group's Adicet Bio position peaked at $9.4K in Q1 2025.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2025.

Based on StoneX Group's 13F filing for Q2 2025, filed 13 Aug 2025.